eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
SCImago Journal & Country Rank

Interview with Professor Janusz Skowronek
ABS 2015
vol. 9
Original paper

Comparison of electronic brachytherapy and Mohs micrographic surgery for the treatment of early-stage non-melanoma skin cancer: a matched pair cohort study

Rakesh Patel, Robert Strimling, Stephen Doggett, Mark Willoughby, Kenneth Miller, Lawrence Dardick, Erick Mafong

J Contemp Brachytherapy 2017; 9, 4: 338-344
Online publish date: 2017/06/23
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Purpose: High-dose-rate electronic brachytherapy (EBT) provides a non-surgical treatment option for non-melanoma skin cancer (NMSC). This matched-pair cohort study compared the outcomes of treatment with EBT to those of Mohs micrographic surgery (MMS) in patients with NMSC.

Material and methods: At four treatment centers, patients treated with EBT were case matched to patients treated with MMS based on retrospectively-collected patient age, lesion size, location and type, and year of treatment. Follow-up data were prospectively collected and included local recurrence, toxicities, cosmesis, and patient-reported outcomes.

Results: The 369 patients (188 in the EBT treatment group and 181 in the MMS treatment group) had 416 lesions (208 in the EBT group and 208 in the MMS group), including 226 basal cell carcinomas (BCC) and 190 squamous cell carcinomas (SCC). Most patients were Caucasian (98.9% and 99.5%) and male (65.4% and 66.3%) of median age 80.7 (range: 61-98) (EBT) and 76.8 (range: 51-98) years (MMS). Most lesions were size > 1 cm and ≤ 2 cm, and located on the head. At mean 3.4 years post-treatment, 99.5% of EBT, and 100.0% of MMS-treated lesions were free of recurrence (p = ns). One recurrence was noted in the EBT group. Physicians rated cosmesis as “excellent” or “good” in 97.6% of EBT-treated lesions, and 95.7% of MMS-treated lesions.

Conclusions: This matched-pair cohort study supports the use of EBT as an effective non-surgical treatment option for NMSC with equivalent recurrence rates and cosmetic outcomes to MMS in appropriately-selected patients with early stage NMSC at extended follow-up.

electronic brachytherapy, Mohs micrographic surgery, NMSC

Delishaj D, Rembielak A, Manfredi B et al. Non-melanoma skin cancer treated with high-dose-rate brachytherapy: a review of literature. J Contemp Brachytherapy 2016; 8: 533-540.
Rogers HW, Weinstock MA, Feldman SR et al. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population. JAMA Dermatol 2015; 151: 1081-1086.
Chen JT, Kempton SJ, Rao VK. The economics of skin cancer: an analysis of Medicare payment data. Plast Reconstr Surg Glob Open 2016; 4:e868.
Alam M, Goldberg LH, Silapunt S et al. Delayed treatment and continued growth of nonmelanoma skin cancer. J Am Acad Dermatol 2011; 64: 839-848.
Steenrod AW, Smyth EN, Bush EN et al. A Qualitative Comparison of Symptoms and Impact of Varying Stages of Basal Cell Carcinoma. Dermatol Ther 2015; 5: 183-199.
Kauvar ANB, Cronin T Jr, Roenigk R et al. Consensus for nonmelanoma skin cancer treatment: basal cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 2015; 41: 550-571.
Kauvar ANB, Arpey CJ, Hruza G et al. Consensus for nonmelanoma skin cancer treatment, Part II: squamous cell carcinoma, including a cost analysis of treatment methods. Dermatol Surg 2015; 41: 1214-1240.
Rowe DE, Carroll RJ, Day CL Jr. Mohs surgery is the treatment of choice for recurrent (previously treated) basal cell carcinoma. J Dermatol Surg Oncol 1989; 15: 424-431.
Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992; 26: 976-990.
Gniadecki R, Glud M, Mortensen K et al. Favorable results of Mohs micrographic surgery for basal cell carcinoma. Dan Med J 2015; 62: A5171.
Caccialanza M, Piccinno R, Moretti D et al. Radiotherapy of carcinomas of the skin overlying the cartilage of the nose: results in 405 lesions. Eur J Dermatol 2003; 13: 462-465.
Bhatnagar A. Electronic brachytherapy for the treatment of non-melanoma skin cancer: results up to 4 years. Int J Radiat Oncol Biol Phys 2014; 90 Suppl: S756.
Kasper ME, Chaudhary AA. Novel treatment options for nonmelanoma skin cancer: focus on electronic brachytherapy. Med Devices (Auckl) 2015; 26: 493-502.
Cognetta A, Howard B, Heaton H et al. Superficial x-ray in the treatment of basal and squamous cell carcinoma: a viable option in select patients. J Am Acad Dermatol 2012; 67: 1237-1241.
Schulte KW, Lippoid A, Auras C et al. Soft x-ray therapy for cutaneous basal cell and squamous cell carcinomas. J Am Acad Dermatol 2005; 53: 993-1001.
Hernández-Machin B, Borrego L, Gil-García M, Hernández BH. Office-based radiation therapy for cutaneous carcinoma: evaluation of 710 treatments. Int J Dermatol 2007; 46: 453-459.
Locke J, Karmpour S, Young G et al. Radiotherapy for epithelial skin cancer. Int J Radiat Oncol Biol Phys 2001; 51: 748-755.
Gauden R, Pracy M, Avery AM et al. HDR brachytherapy for superficial non-melanoma skin cancers. J Med Imaging Radiat Oncol 2013; 57: 212-217.
Köhler-Brock A, Prager W, Pohlmann S et al. The indications for and results of HDR afterloading therapy in diseases of the skin and mucosa with standardized surface applicators (the Leipzig Applicator). Strahlenther Onkol 1999; 175: 170-174.
Dogget S, Willoughby M, Willoughby C et al. Incorporation of Electronic Brachytherapy for Skin Cancer into a Community Dermatology Practice. J Clin Aesthet Dermatol 2015; 8: 28-32.
Bhatnagar A. Nonmelanoma skin cancer treated with electronic brachytherapy: results at 1 year. Brachytherapy 2013; 12: 134-140.
Paravati AJ, Hawkins PG, Martin AN et al. Clinical and cosmetic outcomes in patients treated with high-dose-rate electronic brachytherapy for nonmelanoma skin cancer. Pract Radiat Oncol 2015; 5: e659-e664.
Likhacheva AO, Devlin PM, Shirvani SM et al. Skin surface brachytherapy: A survey of contemporary practice patterns. Brachytherapy 2017; 16: 223-229.
American Joint Committee on Cancer. Cancer Staging System. https://cancerstaging.org/references-tools/Pages/What-is-Cancer-Staging.aspx. Accessed: 23 November 2016.
Axelrod S, Kelley L, Walawalkar A et al. Dosimetric study of a new surface applicator for the Xoft Axxent system. Med Phys 2009; 36: 2532.
Ouhib Z, Kasper M, Perez Calatayud J et al. Aspects of dosimetry and clinical practice of skin brachytherapy: The American Brachytherapy Society working group report. Brachytherapy 2015; 14: 840-858.
Swanson NA. Mohs surgery: Technique, indications, applications, and the future. Arch Dermatol 1983; 119: 761-773.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer. Int J Radiat Oncol Biol Phys 1995; 5: 1341-1346.
Doggett S, Brazil J, Limova M et al. Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions. J Contemp Brachytherapy 2017; 9: 1-3.
Miller K. Electronic brachytherapy: understanding the technology and identifying appropriate use. Practical Dermatology 2015; 47-48.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe